Geron Corporation [NASDAQ: GERN] stock went on an upward path that rose over 8.38% on Tuesday, amounting to a one-week price increase of more than 28.37%. The company report on June 30, 2022 that Geron Corporation Announces Expansion of Existing Loan Facility.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
Up to $50 Million in Additional Non-Dilutive Capital Potentially Available in 2023.
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced an amendment to expand its existing loan facility with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank, from up to $75 million to up to $125 million.
Over the last 12 months, GERN stock rose by 23.97%. The one-year Geron Corporation stock forecast points to a potential upside of 54.75. The average equity rating for GERN stock is currently 1.60, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $634.04 million, with 332.07 million shares outstanding and 297.32 million shares in the current float. Compared to the average trading volume of 2.58M shares, GERN stock reached a trading volume of 5551291 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Geron Corporation [GERN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GERN shares is $4.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GERN stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Robert W. Baird have made an estimate for Geron Corporation shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 02, 2021. While these analysts kept the previous recommendation, B. Riley Securities raised their target price to Buy. The new note on the price target was released on February 18, 2021, representing the official price target for Geron Corporation stock. Previously, the target price had yet another raise to $3, while Stifel analysts kept a Buy rating on GERN stock.
The Average True Range (ATR) for Geron Corporation is set at 0.10, with the Price to Sales ratio for GERN stock in the period of the last 12 months amounting to 452.89. The Price to Book ratio for the last quarter was 6.24, with the Price to Cash per share for the same quarter was set at 0.48.
GERN Stock Performance Analysis:
Geron Corporation [GERN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 28.37. With this latest performance, GERN shares gained by 36.09% in over the last four-week period, additionally plugging by 48.36% over the last 6 months – not to mention a rise of 23.97% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GERN stock in for the last two-week period is set at 76.28, with the RSI for the last a single of trading hit 85.80, and the three-weeks RSI is set at 69.17 for Geron Corporation [GERN]. The present Moving Average for the last 50 days of trading for this stock 1.3914, while it was recorded at 1.6100 for the last single week of trading, and 1.3294 for the last 200 days.
Insight into Geron Corporation Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Geron Corporation [GERN] shares currently have an operating margin of -8183.70 and a Gross Margin at +43.79. Geron Corporation’s Net Margin is presently recorded at -8335.39.
Return on Equity for this stock declined to -68.84, with Return on Assets sitting at -46.75.
Geron Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.80 and a Current Ratio set at 3.80.
GERN Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GERN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Geron Corporation go to 5.00%.
Geron Corporation [GERN] Insider Position Details
There are presently around $305 million, or 49.40% of GERN stock, in the hands of institutional investors. The top three institutional holders of GERN stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 30,126,299, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 24,581,662 shares of the stock with an approximate value of $41.05 million in GERN stocks shares; and VANGUARD GROUP INC, currently with $28.95 million in GERN stock with ownership of nearly 12.382% of the company’s market capitalization.
Positions in Geron Corporation stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 64 institutional holders increased their position in Geron Corporation [NASDAQ:GERN] by around 58,207,514 shares. Additionally, 58 investors decreased positions by around 4,832,672 shares, while 47 investors held positions by with 119,734,693 shares. The mentioned changes placed institutional holdings at 182,774,879 shares, according to the latest SEC report filing. GERN stock had 22 new institutional investments in for a total of 47,742,183 shares, while 24 institutional investors sold positions of 844,868 shares during the same period.